Experimental CAR-T therapy targets Hard-to-Treat gut cancers
NCT ID NCT06197178
First seen Feb 06, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (CAR-T cells) to attack a protein found on certain advanced gastrointestinal tumors. The study involved 17 adults with cancers like colorectal, gastric, or pancreatic cancer that had not responded to other treatments. The main goals were to check safety and find the right dose, but the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROINTESTINAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital & Institute
Beijing, Beijing Municipality, 100142, China
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China
Conditions
Explore the condition pages connected to this study.